Baxalta Inc (BXLT) : Lvm Capital Management Ltdmi reduced its stake in Baxalta Inc by 15.91% during the most recent quarter end. The investment management company now holds a total of 8,325 shares of Baxalta Inc which is valued at $335,914 after selling 1,575 shares in Baxalta Inc according to a report filed by the company on Apr 4, 2016 with the SEC.Baxalta Inc makes up approximately 0.11% of Lvm Capital Management Ltdmi’s portfolio.
Other Hedge Funds, Including ,
On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.
Baxalta Inc opened for trading at $40.41 and hit $40.67 on the upside on Monday, eventually ending the session at $40.35, with a gain of 0.22% or 0.09 points. The heightened volatility saw the trading volume jump to 57,95,483 shares. Company has a market cap of $27,488 M.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.